arbiter
JournalsPricingAccount

Changes in drug price reduction trends during Japan’s transition to an annualized revision environment: a comparative analysis using open data from the national claims database

Koichi Tsuda et al.

Journal of Medical Economics2026https://doi.org/10.1080/13696998.2026.2651056article
ABDC C
Weight
0.50

What the paper says

Japan's annualized revision environment (2020-2023) was associated with an acceleration in pharmaceutical cost containment, but also with bipolarization across product segments. Marked price erosion in oral drugs, together with pronounced therapeutic heterogeneity, suggests that uniform reductions should be reconsidered to safeguard access and continuity of care.

Open paper page →

Cite this paper

https://doi.org/https://doi.org/10.1080/13696998.2026.2651056

Or copy a formatted citation

@article{koichi2026,
  title        = {{Changes in drug price reduction trends during Japan’s transition to an annualized revision environment: a comparative analysis using open data from the national claims database}},
  author       = {Koichi Tsuda et al.},
  journal      = {Journal of Medical Economics},
  year         = {2026},
  doi          = {https://doi.org/https://doi.org/10.1080/13696998.2026.2651056},
}

Paste directly into BibTeX, Zotero, or your reference manager.

Flag this paper

Changes in drug price reduction trends during Japan’s transition to an annualized revision environment: a comparative analysis using open data from the national claims database

Flags are reviewed by the Arbiter methodology team within 5 business days.

Evidence weight

0.50

Balanced mode · F 0.40 / M 0.15 / V 0.05 / R 0.40

F · citation impact0.50 × 0.4 = 0.20
M · momentum0.50 × 0.15 = 0.07
V · venue signal0.50 × 0.05 = 0.03
R · text relevance †0.50 × 0.4 = 0.20

† Text relevance is estimated at 0.50 on the detail page — for your query’s actual relevance score, open this paper from a search result.